OPKO Health, Inc. (NASDAQ:OPK) Stock Position Lowered by Whitefort Capital Management LP

Whitefort Capital Management LP lowered its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 66.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 134,490 shares of the biotechnology company’s stock after selling 268,700 shares during the quarter. OPKO Health accounts for approximately 0.1% of Whitefort Capital Management LP’s investment portfolio, making the stock its 14th largest position. Whitefort Capital Management LP’s holdings in OPKO Health were worth $200,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of OPK. Price T Rowe Associates Inc. MD raised its holdings in shares of OPKO Health by 4.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after purchasing an additional 17,671 shares in the last quarter. Tidal Investments LLC bought a new position in shares of OPKO Health in the first quarter valued at $239,000. Comerica Bank lifted its position in shares of OPKO Health by 125.0% during the 1st quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 50,000 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of OPKO Health during the 1st quarter worth $26,000. Finally, CIBC Asset Management Inc grew its holdings in shares of OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Stock Performance

Shares of OPK opened at $1.57 on Friday. The company’s 50 day moving average price is $1.52 and its 200 day moving average price is $1.46. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 52 week low of $0.85 and a 52 week high of $1.75. The company has a market capitalization of $1.07 billion, a PE ratio of -8.26 and a beta of 1.62.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was purchased at an average price of $1.62 per share, with a total value of $162,000.00. Following the transaction, the chief executive officer now directly owns 211,612,405 shares in the company, valued at approximately $342,812,096.10. The trade was a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders bought 679,255 shares of company stock valued at $1,045,855. 47.26% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.